MedTrace Logo

Citicoline in Ischemic Stroke

NCT05154903 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-02-17

No results posted yet for this study

Summary

There is evidence that citicoline is the only neuroprotectant able to improve the functional status of the patients after an acute ischemic stroke.

Citicoline is a neuroprotectant drug against cerebral ischemia, with positive results, both in experimental and clinical trials, in the treatment of acute stroke and head injuries

Also, the safety profile of citicoline is good, and there are no associated problems when the drug is used in this kind to patients

The aim of this study is to confirm the efficacy and safety of citicoline in patients with moderate-to-severe acute ischemic stroke in Egypt, according to the characteristics of the medical care in this country

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Citicoline 500 MG

Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.

Sponsors & Collaborators

  • Kafrelsheikh University

    collaborator OTHER

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-22
Primary Completion
2022-04-22
Completion
2022-06-22

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05154903 on ClinicalTrials.gov